Cartesian Therapeutics autoimmune disorder therapy meets main goal of mid-stage study
02/07/2024 11:35
July 2 (Reuters) - Cartesian Therapeutics RNAC.O said on Tuesday that its experimental autoimmune disorder therapy met the main goal of a mid-stage trial. (Reporting by Sneha S K in Bengaluru; Editing by Shailesh Kuber) ((Sneha.SK@thomsonreuters.com;))
Recent news on Cartesian Therapeutics
See all newsBrief: Cartesian Therapeutics Announces Additional Retreatment Data For Descartes-08 Highlighting Deep And Durable Responses In Patients With Myasthenia Gravis
Cartesian Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cartesian Therapeutics Q2 net income steady
Brief: Cartesian Therapeutics Inc Q2 Net Income USD 15.769 Million
Cartesian Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview